ReviewCurrent hypertension reviews2026
A Contemporary Review of Myocardial Infarction with Emphasis on Clinical Trials and Therapeutic Approaches.
Review in Current hypertension reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myocardial infarction (MI), a major manifestation of coronary artery disease, remains a global health challenge despite significant advances in research and therapy. This review highlights current developments in diagnostic criteria, pathophysiology, treatment strategies, and emerging therapeutic targets. Type 1 MI, driven by atherosclerotic plaque rupture and thrombosis, continues to dominate, but growing recognition of type 2 MI and MINOCA (myocardial infarction with nonobstructive coronary arteries) underscores the need for refined diagnostic and therapeutic approaches. High-sensitivity cardiac troponins and advanced imaging have improved early detection, classification, and risk stratification. The management now emphasizes personalized, evidence-based care, including percutaneous coronary intervention or thrombosis, dual antiplatelet therapy, lipid-lowering agents, and cardioprotective drugs. Despite improved outcomes, challenges, such as late presentation, treatment disparities, recurrent events, and progression to heart failure, persist. A comprehensive literature search was conducted using electronic databases, such as Web of Science, Google Scholar, PubMed, SciFinder, Reaxys, and the Cochrane Library. By identifying persistent gaps, this work aimed to inform clinicians, researchers, and policymakers on innovative strategies for prevention, early detection, and optimal MI management.
Indexed as
Identifiers
42897896What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.